^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like)

    i
    Other names: SH3BGRL, SH3 Domain Binding Glutamate Rich Protein Like, SH3 Domain Binding Glutamic Acid-Rich Protein Like, SH3 Domain-Binding Glutamic Acid-Rich-Like Protein, MGC117402, SH3-Binding Domain Glutamic Acid-Rich Protein Like, Epididymis Secretory Protein Li 115, HEL-S-115, SH3BGR
    3ms
    SH3BGRL2 as a vital tumor suppressor and prognostic factor in human esophageal squamous cell carcinoma. (PubMed, J Thorac Dis)
    Notably, early growth response 1 (EGR1) expression was elevated in SH3BGRL2-silenced PDCs, suggesting that SH3BGRL2 may suppress ESCC proliferation by blocking the EGR1 pathway. SH3BGRL2 acts as a key tumor suppressor and prognostic determinant in ESCC, which represents a novel insight into the pathogenesis of this malignancy.
    Journal
    |
    SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • EGR1 (Early Growth Response 1)
    8ms
    Mutant p53 induces SH3BGRL expression to promote cell engulfment. (PubMed, Cell Death Discov)
    Through FACS sorting of pure cell engulfing (CIC) populations, we could also show that engulfing cells have an enhanced etoposide resistance. These data suggest that SH3BGRL and cell engulfment are required for certain GOFs of mutant p53.
    Journal
    |
    TP53 (Tumor protein P53) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like)
    |
    TP53 mutation
    |
    etoposide IV
    over1year
    ALKBH5 modulates m6A modification to enhance acute myeloid leukemia resistance to adriamycin. (PubMed, Biomol Biomed)
    In vivo, ALKBH5 knockdown inhibited ADR resistance in AML cells. In conclusion, ALKBH5 removed m6A modification to stabilize TUG1 expression in a YTHDF2-dependent manner, enhancing H3K9me2 levels on the SH3BGRL promoter and suppressing SH3BGRL expression, thus promoting ADR resistance in AML cells.
    Journal
    |
    SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • ALKBH5 (AlkB Homolog 5, RNA Demethylase) • TUG1 (Taurine Up-Regulated 1) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    |
    doxorubicin hydrochloride
    over1year
    Chromosome X-wide association study in case control studies of pathologically confirmed Alzheimer's disease in a European population. (PubMed, Transl Psychiatry)
    We have also identified SNPs in the NXF5 gene at chromosome-wide significance in females (rs5944989, OR = 0.62, p = 1.1e-05) but not in males (p = 0.83). The discovery of relevant AD associated genes on the X chromosome may identify AD risk differences and similarities based on sex and lead to the development of sex-stratified therapeutics.
    Clinical • Journal
    |
    IL1RAP (Interleukin 1 Receptor Accessory Protein) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • DDX53 (DEAD-Box Helicase 53)
    2years
    A Systems Biology Approach for Investigating Significant Biomarkers and Drug Targets Common Among Patients with Gonorrhea, Chlamydia, and Prostate Cancer: A Pilot Study. (PubMed, Bioinform Biol Insights)
    Three potential therapeutic compounds namely INCB3284, CCX915, and MLN-1202 were found to interact with up-regulated protein C-C chemokine receptor type 2 (CCR2) in protein-drug interaction analysis. The proposed biomarkers and therapeutic potential molecules could be investigated for potential pharmacological targets and activity in the fight against in patients with gonorrhea, chlamydia, and prostate cancer.
    Journal
    |
    SLFN11 (Schlafen Family Member 11) • GATA6 (GATA Binding Protein 6) • APP (Amyloid Beta Precursor Protein) • KMT2B (Lysine Methyltransferase 2B) • MIR7 (MicroRNA 7) • CCR2 (C-C Motif Chemokine Receptor 2) • HIVEP1 (HIVEP Zinc Finger 1) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • DERL1 (Derlin 1) • MARCKS (Myristoylated Alanine Rich Protein Kinase C Substrate) • PRNP (Prion Protein) • PTGS1 (Prostaglandin-Endoperoxide Synthase 1) • SLC40A1 (Solute Carrier Family 40 Member 1)
    |
    plozalizumab (TAK-202)
    over2years
    Gene expression profiles to analyze the anticancer and carcinogenic effects of arsenic in bladder cancer. (PubMed, Am J Transl Res)
    Arsenic exerted carcinogenic and anticancer functions by altering the expression of crosstalk genes such as BDKRB2, FOS, NR4A1, PLAU, SH3BGRL, and F10, and these were due to arsenic binding proteins.
    Journal • Gene Expression Profile • PARP Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • BACH1 (BTB Domain And CNC Homolog 1) • NR4A1 (Nuclear Receptor Subfamily 4 Group A Member 1) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • PLAU (Plasminogen Activator) • ZFP36 (ZFP36 Ring Finger Protein)
    |
    arsenic trioxide
    over2years
    Gene SH3BGRL3 regulates acute myeloid leukemia progression through circRNA_0010984 based on competitive endogenous RNA mechanism. (PubMed, Front Cell Dev Biol)
    We also studied the transfection plasmid vector (PLVX-SHRNA2-PURO) combined with a drug (daunorubicin) to observe the therapeutic effect... We found that SH3BGRL3 and circRNA_0010984 are important to AML. circRNA_0010984 was significantly up-regulated in AML and promoted cell proliferation by regulating miR-375 through molecular sponge action.
    Journal
    |
    YAP1 (Yes associated protein 1) • MIR375 (MicroRNA 375) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like)
    |
    daunorubicin
    over2years
    Integrated analysis of single-cell and bulk transcriptome identifies a signature based on NK cell marker genes to predict prognosis and therapeutic response in clear cell renal cell carcinoma. (PubMed, Transl Cancer Res)
    In two therapy cohorts of ccRCC patients (PMID32472114 and E-MTAB-3267), we demonstrated that high-risk group showed greater sensitivity to ICIs, whereas the low-risk group was more likely to benefit from anti-angiogenic therapy. We identified a novel signature that can be utilized as an independent predictive biomarker and a tool for selecting the individualized treatment for ccRCC patients.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • CD7 (CD7 Molecule) • PLAC8 (Placenta Associated 8) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • CALM1 (Calmodulin 1)
    almost3years
    SH3BGRL Suppresses Liver Tumor Progression through Enhanced ATG5-Dependent Autophagy. (PubMed, J Oncol)
    The relevance of SH3BGRL downregulation in liver cancers and their progression is validated based on the large-scale tumor data. Taken together, our results clarify the suppressive role of SH3BGRL in tumorigenesis of liver cancer, which would be of help to the diagnosis of liver cancer, while either promoting the autophagy of liver cancer cells or inhibiting the downstream signaling induced from SH3BGRL downregulation would be a promising therapy.
    Journal
    |
    ATG5 (Autophagy Related 5) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like)
    |
    ATG5 overexpression • SH3BGRL overexpression • ATG5 expression
    almost3years
    Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer. (PubMed, Front Endocrinol (Lausanne))
    High-ENZ-sig patients were more sensitive to cell cycle-targeted drugs (MK-1775, AZD7762, and MK-8776) than low-ENZ-sig patients in PCa. Our results provided evidence and insight on the potential utility of ENZ-sig in PCa prognosis and combination therapy strategy of enzalutamide and cell cycle-targeted compounds in treating PCa.
    Journal
    |
    SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • COL5A2 (Collagen Type V Alpha 2 Chain)
    |
    Xtandi (enzalutamide) • adavosertib (AZD1775) • MK-8776 • AZD-7762
    over3years
    Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology (ASH 2022)
    Discussion In conclusion, by leveraging the largest single-cell RNA-sequencing cohort of bone marrow samples from patients with MGUS and SMM, we uncovered novel insights into plasma cell malignancy, as well as differences in gene expression dysregulation between disease stages. Observations gleaned from this dataset could be used to nominate novel targets and prioritize target validation for the development of novel therapeutics for the treatment or prevention of MM.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IGF1 (Insulin-like growth factor 1) • CD27 (CD27 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD99 (CD99 Molecule) • SH3BGRL (SH3 Domain Binding Glutamate Rich Protein Like) • TJP1 (Tight Junction Protein 1) • CD81 (CD81 Molecule) • SLAMF7 (SLAM Family Member 7) • TXNDC11 (Thioredoxin Domain Containing 11)